Bafrekalant 是一种二氮杂双环取代的咪唑并[1,2-a]嘧啶衍生物。Bafrekalant 具有研究呼吸障碍的潜力，包括与睡眠相关的呼吸障碍，如阻塞性和中枢性睡眠呼吸暂停和打鼾 (信息提取自专利 WO2018228907A1)。
| Cas No. | 2256770-44-0 |
| 分子式 | C29H31ClN6O2 |
| 分子量 | 531.05 |
| 溶解度 | DMSO : 250 mg/mL (470.77 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1). [1]. Martina Delbeck, et al. Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders. Patent WO2018228907A1. |
